miraDry®

Common problem. Lasting solution.

The first and only FDA-cleared device for treating excessive underarm sweat that provides a **lasting solution**

Breakthrough **non-invasive** microwave technology safely eliminates underarm sweat glands and provides a **lasting** reduction of underarm sweat

- ✓ Lasting and stable efficacy
- ✓ Strong safety profile
- ✓ High patient satisfaction
- ✓ Minimal to no patient downtime
- ✓ FDA-cleared to treat excessive underarm sweat



Microwave Energy is Ideal for Treating Underarm Sweat

- ✓ Maximum destruction of sweat gland network
- ✓ Minimal impact to surrounding tissues
- ✓ Non-invasive

Controlled thermolysis caused by **precisely** delivered energy

1

Targeted energy delivery to the dermal-fat interface region

- Virtually all the sweat glands reside here



2

Focal Energy Zone created along interface, independent of skin thickness

- Energy reflected due to electromagnetic properties in the interface
- Energy intensified from constructive interference



3

Thermolysis at 60°+ C

- Hydro-ceramic cooling keeps Heat Zone at level of sweat glands
- Cooling protects epidermis and upper dermis, while deeper tissue not affected
- Lasting solution since sweat glands do not regenerate[1]



miraDry Procedure Delivers Stellar Results

miraDry Commercial Device Study[2,3]

31 adult subjects
2 sites

- **Dramatic, lasting** and **stable** efficacy at final study visit at 24 months

>90% Clinical Efficacy and Stability

(% Subjects with HDSS Reduction to 1 or 2)



82% Average Sweat Reduction

(Gravimetric)



Dramatic Reduction in DLQI



High Patient Satisfaction



miraDry Randomized, Blinded Study demonstrates stable efficacy[5]

120 adult subjects
7 sites

- Stable efficacy through final study visit 12 months after treatment
- Statistically significant difference between treated and sham groups
- Randomized, blinded, sham controlled study with investigational system
- Data used for FDA clearance
- Published in peer-reviewed journal

miraDry®
Common problem. Lasting solution.

Millions of patients suffer silently

- **1 in 5** U.S. adults ages 18-49 suffer from excessive underarm sweat[6]
- Yet most patients who think they have too much sweat have never consulted a healthcare professional
  - Embarrassment factor
  - Think it's normal to sweat that way
  - Lack awareness that it can be treated
  - Not satisfied with conventional treatment options
- Miramar Labs will help you address this large market opportunity

Only the miraDry procedure addresses all key patient needs

Treatment	Efficacy	Lasting	Non-Invasive	Minimal / No Downtime
miraDry	✔	✔	✔*	✔
Prescription Antiperspirants	Poor	Daily Use	✔	✔
Botulinum Toxin A	✔	Temporary (Mean Duration of 6.7 Months[7])	Injections using a fine needle	✔
Surgery (liposuction or ETS†)	Technique Dependent	✔	Minimally-Invasive/ Invasive	Extended Recovery and Downtime
Systemic Anticholinergics	Not Established	Daily Use	✔	✔

* Pre-procedure preparation requires local anesthesia
† ETS = Endoscopic Thoracic Sympathectomy

The miraDry System is FDA cleared for the treatment of primary axillary hyperhidrosis in adults 18 and over.

1 "The ontogenesis of sweat glands is only at the embryonic period, so no new sweat glands are regenerated after birth." Li H, Gang Z, et al. Antigen Expression of Human Eccrine Sweat Glands. J Cutan Pathol 2009: 36: 318-324.

2 Lupin MS and Hong C-H. Presented at American Society for Dermatologic Surgery Annual Meeting; October 11-14, 2012; Atlanta, GA.

3 Chih-Ho Hong, MD, Mark Lupin, MD et al; Dermatol Surg 2012; 38:728-735.

4 Kowalski JW et al. J Am Acad Dermatol 2007; 52: AB52.

5 Glaser DA, Coleman WP, Fan LK, et al. Dermatol Surg 2012; 38:185-191.

6 November 2009 Ipsos Vantis Market Study with 661 consumers (# of sweat events not related to athletics); clinical segment clinically diagnosed, sweat-bothered score >7 on 10-point scale. Data on file.

7 Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary hyperhidrosis: a 52 week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007; 56:604-611.

www.miraDry.com

miramarlabs®

445 Indio Way • Sunnyvale, CA 94085 • 408-940-8700

MK0019 Rev. F 10/12